Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Tausch, Eugen  [Clear All Filters]
2016
Scheffold A, Jebaraj BMichael Ch, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, et al. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. Br J Haematol. 2016.
2022
von Tresckow J, Cramer P, Robrecht S, Langerbeins P, Fink A-M, Al-Sawaf O, Fürstenau M, Illmer T, Klaproth H, Tausch E, et al. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia. 2022.
2023
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388(19):1739-1754.
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink A-M, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, et al. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nat Med. 2023.
2024
Cramer P, von Tresckow J, Fink A-M, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, et al. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Am J Hematol. 2024.